This, together with the evidence that decreased nuclear translocation of PKCδ promotes B cell survival [15,16,19], prompted us to evaluate the therapeutic potential of two PKCδ activators, AD 198 and PEP005, in TRAF3-/- mouse B lymphomas and human MM cells. The gene discussed is PRKCD; the disease is Miyoshi myopathy.